Bevacizumab Treatment for Vestibular Schwannoma in a Patient with Neurofibromatosis Type 2: Hearing Improvement and Tumor Shrinkage
暂无分享,去创建一个
[1] P. Cayé-Thomasen,et al. The effect of bevacizumab on vestibular schwannoma tumour size and hearing in patients with neurofibromatosis type 2 , 2015, European Archives of Oto-Rhino-Laryngology.
[2] P. de Souza,et al. Systemic therapy in neurofibromatosis type 2. , 2014, Cancer treatment reviews.
[3] A. Muzikansky,et al. Long-term toxicity of bevacizumab therapy in neurofibromatosis 2 patients , 2014, Cancer Chemotherapy and Pharmacology.
[4] R. McLendon,et al. Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series , 2012, Journal of Neuro-Oncology.
[5] I. Yang,et al. The molecular biology and novel treatments of vestibular schwannomas. , 2011, Journal of neurosurgery.
[6] R. Jain,et al. Anti-vascular endothelial growth factor therapies as a novel therapeutic approach to treating neurofibromatosis-related tumors. , 2010, Cancer research.
[7] R. Jain,et al. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. , 2009, The New England journal of medicine.
[8] J. Butman,et al. Neurofibromatosis type 2 , 2009, The Lancet.
[9] Susan M. Chang,et al. Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma , 2009, Journal of Neuro-Oncology.
[10] P. Cayé-Thomasen,et al. VEGF and VEGF Receptor-1 Concentration in Vestibular Schwannoma Homogenates Correlates to Tumor Growth Rate , 2005, Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology.
[11] J. Liu. Bevacizumab treatment for vestibular schwannomas in neurofibromatosis type two: report of two cases, including responses after prior gamma knife and vascular endothelial growth factor inhibition therapy , 2012 .